Evidence map›Paper›PMID 41201892›Full record

Observational studyAntimicrobial agents and chemotherapy2025

Effectiveness of imipenem-relebactam for multidrug-resistant

Walaiporn Wangchinda, Janet Y Wu, Lilian M Abbo, Renee Ackley, Patricia Bartley, Mayan Gilboa, Jeffrey Harrington, Rupal Jaffa, Megan E Klatt, Ellen G Kline and 12 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Real-World Antibiotic Strategies for Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Prevalence and characterization ofOpen veterinary journal · 2026
    Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Walaiporn WangchindaUniversity of Michigan, College of Pharmacy, Ann Arbor, Michigan, USA.
Janet Y WuDepartment of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
Lilian M AbboDivision of Infectious Diseases, Miller School of Medicine, University of Miami, Miami, Florida, USA.ORCID 0000-0002-2364-8358
Renee AckleyAtrium Health, Charlotte, North Carolina, USA.
Patricia BartleyDepartment of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
Mayan GilboaDeptarment of Infection Control & Antimicrobial Stewardship, Jackson Memorial Hospital, Miami, Florida, USA.
Jeffrey HarringtonUniversity of Michigan, College of Pharmacy, Ann Arbor, Michigan, USA.
Rupal JaffaAtrium Health, Charlotte, North Carolina, USA.
Megan E KlattDepartment of Pharmacy, Kansas University Medical Center, Kansas, Missouri, USA.
Ellen G KlineDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0006-7167-6368
Ryan C KubatDepartment of Pharmacy, Kansas University Medical Center, Kansas, Missouri, USA.
Alexander J LepakUniversity of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin, USA.
Erin K McCrearyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6705-2225
William R MillerDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-1518-2973
Jeffrey C PearsonDepartment of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5276-1050
Sunish ShahUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Truc T TranDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-2696-4196
Ana VegaDeptarment of Infection Control & Antimicrobial Stewardship, Jackson Memorial Hospital, Miami, Florida, USA.ORCID 0000-0003-1974-4547
Melissa VendettiMerck & Co Inc, Rahway, New Jersey, USA.
Emre YucelMerck & Co Inc, Rahway, New Jersey, USA.ORCID 0000-0002-6036-9526
Jason M PogueUniversity of Michigan, College of Pharmacy, Ann Arbor, Michigan, USA.ORCID 0000-0003-4780-6215
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9794-5665

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Rahway, NJ, USA naNCATS NIH HHS UL1 TR001857
6 · The paper itself

Abstract

Imipenem-relebactam demonstrates

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsBacteremiaImipenemPneumonia, BacterialPseudomonas aeruginosaPseudomonas InfectionsAgedDrug Resistance, Multiple, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedRetrospective StudiesTreatment OutcomeAnti-Bacterial AgentsAzabicyclo CompoundsImipenemrelebactamimipenem-relebactampneumoniaPseudomonasresistance

Identifiers

PMID41201892
PMCPMC12691631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.